Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Alector, Inc. develops clinical-stage biotechnology programs for neurodegenerative diseases, using genetics, immunology and neuroscience to pursue therapies that remove toxic proteins, replace missing proteins and restore immune and nerve cell function. News about ALEC commonly covers the Alector Brain Carrier (ABC) blood-brain barrier platform and ABC-enabled programs across antibodies, enzymes and siRNA.
Company updates focus on Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia and other tauopathies, including candidates such as AL137, AL050 and AL064/AL164, as well as prior clinical programs including nivisnebart and latozinemab. Recurring announcements also include financial results, cash runway commentary, clinical trial results or discontinuations, research pipeline progress, investor conference participation and executive leadership changes.
Alector, a clinical-stage biotechnology company based in South San Francisco, reported participation in two upcoming investor conferences. The events include the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 3:20 p.m. ET, and the Stifel 2022 Healthcare Conference on November 16, 2022, at 8:00 a.m. ET. Both presentations will be available via webcast on Alector's website, with replays accessible for 90 days post-event. Alector focuses on immuno-neurology and innate immuno-oncology, targeting neurodegenerative diseases through innovative therapeutic approaches.
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology firm, announced on November 1, 2022, the grant of stock options and restricted stock units (RSUs) to five new employees under its 2022 Inducement Equity Incentive Plan. A total of 202,080 stock options and 101,039 RSUs were awarded, with an exercise price of $9.29 per share. The options vest over four years, while RSUs vest over three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment, reflecting Alector's commitment to enhancing its workforce in immuno-neurology and immuno-oncology.
Alector (Nasdaq: ALEC) has promoted Clare Hunt to Chief People Officer, enhancing its commitment to employee culture and development. Since 2017, Hunt has contributed to a workforce growth of 44%, now exceeding 270 employees, with notable representation of women in leadership (50%) and R&D (64%). Alector has received the Great Place to Work® certification for three consecutive years and was listed in Fortune's “Best Workplaces in Biopharma” for the second year. This promotion reflects Alector's strategy to align talent acquisition with its growth objectives.
Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on immuno-neurology, has granted stock options and restricted stock units (RSUs) to six new employees. The awards include options for 103,462 shares at an exercise price of $9.46, matching the closing price on September 30, 2022. These options have a ten-year term and will vest over four years, while RSUs will vest over three years. This compensation is part of the 2022 Inducement Equity Incentive Plan and aims to attract talent critical to Alector’s innovative work in treating neurodegenerative diseases.
Alector, Inc. (Nasdaq: ALEC) has initiated a Phase 1 clinical trial for AL044, its first-in-class drug candidate targeting the MS4A gene, a significant genetic risk factor for Alzheimer’s disease (AD). The trial will evaluate the safety, pharmacokinetics, and target engagement of AL044 in approximately 72 healthy participants. AL044 aims to modulate microglia to address multiple AD pathologies. Alector's approach represents a novel strategy to treat neurodegeneration, contrasting with existing therapies. The company is also advancing two additional drug candidates for AD.
Alector, a clinical-stage biotechnology company focused on immuno-neurology, announced its participation in two upcoming investor conferences in New York. The H.C. Wainwright 24th Annual Global Investment Conference is scheduled for September 12, 2022, featuring an on-demand corporate presentation at 7:00 a.m. ET. Subsequently, Alector will engage in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference later that day at 5:25 p.m. ET. Webcasts of these events will be accessible on Alector's website for 90 days.
Alector, Inc. (Nasdaq: ALEC) recently reported its Q2 2022 financial results, highlighting revenue growth and significant advancements in its clinical pipeline. The company achieved $79.9 million in collaboration revenue, a significant increase from $6.6 million in Q2 2021, primarily due to the AbbVie Agreement. Alector's cash position stands at $808.9 million, providing operational runway into H2-2024.
The company submitted an IND application for AL044, targeting Alzheimer’s disease, and continues to expand clinical sites for the pivotal INFRONT-3 study of latozinemab (AL001).
Alector, a clinical-stage biotechnology company, announced participation in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, at 2:00 p.m. PT. The live webcast will be accessible on Alector's Investors page, with a replay available for 90 days post-event. Alector is known for its innovative approach in immuno-neurology, targeting immune dysfunction to treat neurodegenerative diseases like Alzheimer’s and frontotemporal dementia.
Alector, Inc. (Nasdaq: ALEC) announced on May 27, 2022, that its board approved an inducement equity grant for Gary Romano, M.D., Ph.D., its new Chief Medical Officer. The grant includes inducement stock options for 369,000 shares and restricted stock units (RSUs) for 92,250 shares, aligned with the 2022 Inducement Equity Incentive Plan. The options have an exercise price of $9.20 per share and vest over four years, while the RSUs vest quarterly over three years, starting September 1, 2022. This move aims to attract talent amid growing operations in immuno-neurology.
Alector, Inc. (Nasdaq: ALEC) reported promising results from the INFRONT-2 Phase 2 clinical trial of AL001 (latozinemab), showing a 54% annual delay in disease progression for FTD-C9orf72 patients compared to controls. The drug increased progranulin levels significantly, supporting its role in treating neurodegenerative diseases. Alector's cash reserves stand at $868.6 million, ensuring operational funds through mid-2024. Leadership has been strengthened with new appointments, enhancing their clinical and financial strategies.